$AFRM

AFRM Stock Clocks 4 Days In The Red: One Analyst Still Sees 13% Upside After Trimming Target

Affirm Holdings (AFRM) shares fell 0.3% in overnight trading, extending a four-day losing streak. Morgan Stanley lowered its price target to $79 but still sees 13% upside. Monness Crespi initiated coverage with a 'Buy' rating and a $90 target. Analysts expect Q1 revenue of $1.21B and EPS of $0.38. AFRM stock is down 6% YTD.

Original reporting
Published Oct 27, 2026, 1:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AFRM
Neutral
medium confidence
Mentioned
$AFRM
Relevance
6/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$AFRMNeutralMed
01

Why it matters

Analyst coverage changes provide fresh guidance ahead of the Q1 earnings release, offering a short‑term trading cue.

02

Market read

Target adjustments ahead of earnings provide a modest trading signal; the stock’s near‑term direction hinges on the upcoming earnings report and broader rate‑policy environment.

03

What to watch

Potential Fed rate decision impact on consumer credit demand could outweigh the analyst target change.

Relevance 6/10Novelty 5/10Timing: pre‑market today

Background

Affirm is a fintech firm offering buy‑now‑pay‑later services; its stock has slipped 0.3% after four losing sessions amid rate‑sensitivity concerns.

Company-level read

Ticker impact

$AFRMNeutralMedium confidence
Context

Morgan Stanley trimmed its price target to $79 and Monness Crespi initiated coverage with a $90 target ahead of the Q1 earnings release.

Expected impact

modest downside as the market prices in the lower target, though upside remains possible if earnings beat expectations

Evidence & confidence

Analyst target cuts are fresh information, but the move is modest and the earnings report is still days away.

Market effects

Buy‑now‑pay‑later sector may see slight re‑rating as analysts adjust targets.

U.S. market participants tracking fintech earnings will note the target change.

Limited; primarily affects U.S. fintech investors.

Counterpoint

The target cut could be an over‑reaction; the stock may rally on the upcoming earnings beat.

Key entities

  • Affirm Holdings Inc.

    Buy‑now‑pay‑later fintech whose stock ticker is AFRM.

  • Morgan Stanley

    Reduced AFRM price target to $79.

  • Monness Crespi

    Initiated coverage with a $90 target.

Related articles

$AFRMLow

Affirm claws back into Walmart's orbit with an exclusive Sam's Club deal

Affirm signed an exclusive, multi-year deal with Sam's Club, Walmart's warehouse club chain, to become its pay-over-time provider. The service will launch online soon and in physical stores in 2027. Affirm lost Walmart's BNPL partnership to Klarna in 2025, which impacted its revenue. Affirm's stock closed down 1.51% on the announcement. Affirm's Q3 revenue grew 33% YoY to $1.04B, with GMV up 35% to $11.6B. Klarna's stock has fallen 56% since its IPO.

$AFRMMed

Affirm Lost Walmart to Klarna in 2025. Now It Has Sam’s Club. Here’s What Moves the Stock Before November 5

Affirm (AFRM) signed a multi-year deal with Sam's Club, Walmart's subsidiary, to become its pay-over-time provider. The stock closed down 1.51% at $72.40 on the announcement day. Affirm lost Walmart to Klarna in 2025, which contributed 5% of its GMV and 2% of adjusted operating income. The company is set to report fiscal first-quarter results on November 5.

$AFRMHigh

Why is Affirm stock sliding today?

Affirm stock fell 10.3% to $69.85 after hotter-than-expected CPI data raised Fed rate hike fears, increasing funding costs for its loans. Goldman Sachs cut its price target to $103. The NASDAQ slid 2%, and fintech peers also declined, with Affirm being the most affected due to its borrowing-dependent model.

$AFRMMed

Is Affirm Holdings, Inc. (AFRM) Stock a Buy After Goldman Sachs Raised Its Price Target?

Affirm Holdings (AFRM) saw its price target raised by Goldman Sachs to $115 from $106, citing strong Q4 results with revenue up 33% to $1.2B and operating income up $89M. The company's growth is driven by increased interest-bearing loans and the Affirm Card, with active cardholders doubling. However, risks include credit quality and competition in the BNPL space. Hedge fund holdings declined, and short interest is modest.

$AFRMMed

Affirm (AFRM) Stock Surges 5% on Transformer AI Model Launch for Credit Decisions

Affirm (AFRM) stock rose 5.5% premarket after launching an AI model for instant loan approvals, improving transaction completion rates by 3.4%. The system uses 14 years of proprietary data. Chief Accounting Officer Siphelele Jiyane sold $1.95M in shares. Analysts have a 'Moderate Buy' rating with a $98.78 price target, above the current $71.58. Q2 earnings beat estimates with $4.62 EPS and $1.07B revenue.

$AFRMMed

Affirm stock surges on new AI model for loan approvals

Affirm Holdings Inc (AFRM) shares rose 5.5% premarket after launching an AI model for real-time loan approvals. The model, live in the U.S., uses machine learning to analyze credit history, approving more loans with better performance. According to the company, it increased completed purchases by 3.4% compared to a control group. The technology aims to responsibly expand credit access without compromising repayment rates.